Program
rocakinogene sifuplasmid
Also written as “INO-9012”, “INO-9112” and “INO-4212 + INO-9012”.
Its studies are mostly in Glioblastoma · Carcinoma, Transitional Cell · Hepatitis B · Hemorrhagic Fever, Ebola · Breast Neoplasms, led by 2 companies.
Drug pageRocakinogene sifuplasmid: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Inovio Pharmaceuticalsits history only | 61 open or running | phase 2since Apr 2, 2018 | Sep 11, 2014 | Dec 31, 2027phase 2 · NCT03491683 |
| Geneos Therapeutics | 22 open or running | phase 2since Jan 27, 2020 | Jan 27, 2020 | Sep 2029phase 2 · NCT07722741 |
Also a collaborator on its studies: GeneOne Life Science.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Geneos Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2019Named rocakinogene sifuplasmidINNProposed as its International Nonproprietary Name in WHO's List 122 · before, INO-9012, INO-9112
- Jan 27, 2020First study: phase 2 study in HCCFirst studyNCT04251117 · 36 enrolled · United States, New Zealand
- Jul 20, 2026Phase 2 study in HCCNCT07722741 · 90 planned · United States, New Zealand
Ahead
- Sep 2029Primary completion: phase 2 study in HCCNCT07722741
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Geneos Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722741HCC · United States, New Zealand | 2 | Recruiting | Sep 2029 | 90 |
| NCT04251117HCC · United States, New Zealand | 2 | Active, not recruiting | Nov 29, 2024 | 36 |
How it is read
Names in the registry
- “INO-9012”, 5 entries
- “INO-9112”, 1 entry
- “INO-4212 + INO-9012”, 1 entry
- “INO-4201 + INO-9012”, 1 entry
- “INO-3106, INO-9012”, 1 entry
Conditions, from the studies’ own filings
- Glioblastoma, 1 study
- Carcinoma, Transitional Cell, 1 study
- Hepatitis B, 1 study
- Hemorrhagic Fever, Ebola, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.